tiprankstipranks
Oxford BioMedica plc (GB:OXB)
LSE:OXB
UK Market
OXB
Oxford BioMedica
RESEARCH TOOLSreports
Want to see GB:OXB full AI Analyst Report?

Oxford BioMedica (OXB) Earnings Dates, Call Summary & Reports

113 Followers

Earnings Data

Report Date
Sep 23, 2026
TBA (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
-0.24
Last Year’s EPS
-0.25
Same Quarter Last Year
Analyst Consensus
Moderate Buy
Based on 2 Analysts Ratings

Earnings Call Summary

Q4 2024
Earnings Call Date:Apr 09, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with significant revenue growth, increased client orders, operational efficiency improvements, and strategic expansions. However, challenges such as the operating EBITDA loss and negative working capital movement were noted.
Company Guidance
In the 2024 analyst briefing, OXB reported strong financial performance with an impressive organic revenue growth of 81%, resulting in total revenues of GBP128.8 million, a 44% increase from the previous year. Their pipeline expanded by 30% to $570 million, and customer orders grew by 35% to GBP186 million. The company achieved an operating EBITDA profit of GBP5 million in the second half of the year, narrowing their annual operating EBITDA loss to GBP15.3 million, a significant improvement from 2023's GBP52.8 million loss. For 2025, OXB expects revenues between GBP160 million and GBP170 million, with over 80% of this already covered by existing orders. The company plans to achieve a low single-digit million operating EBITDA profit, with a focus on continued margin expansion driven by operational efficiencies and strong commercial momentum.
Impressive Organic Revenue Growth
The company achieved an organic revenue growth of 81% and total revenues increased by 44% to GBP128.8 million in 2024.
Record Client Orders
The contracted value of client orders reached GBP186 million in 2024, a 35% increase from the previous year.
Operational Efficiency
Operating EBITDA loss narrowed significantly from GBP52.8 million in 2023 to GBP15.3 million in 2024, with a GBP5 million operating EBITDA profit in the second half of 2024.
Strong Commercial Momentum
The company reported significant growth in its pipeline, with a risk-adjusted pipeline growth of 61% from 2022 to 2024.
Successful FDA Inspection
The FDA inspection of the Oxford manufacturing site in July 2024 resulted in zero written observations, highlighting the quality management system.
Strategic Expansion and Rebranding
Completed acquisition of OXB in France, expanding operational footprint, and rebranded as OXB establishing a unified brand across geographies.

Oxford BioMedica (GB:OXB) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
Daily Earnings Calendar >

GB:OXB Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Sep 23, 2026
2026 (Q2)
-0.24 / -
-0.254―――
Mar 26, 2026
2025 (Q4)
-0.08 / -0.05
-0.07729.87% (+0.02)
Sep 23, 2025
2025 (Q2)
-0.24 / -0.25
-0.30917.80% (+0.05)
Apr 09, 2025
2024 (Q4)
-0.08 / -0.08
-1.13493.21% (+1.06)
Sep 23, 2024
2024 (Q2)
-0.28 / -0.31
-0.49737.83% (+0.19)
Apr 29, 2024
2023 (Q4)
-0.49 / -1.13
-0.145-682.07% (-0.99)
Sep 20, 2023
2023 (Q2)
-0.36 / -0.50
-0.273-82.05% (-0.22)
Apr 25, 2023
2022 (Q4)
-0.07 / -0.14
0.011-1418.18% (-0.16)
Sep 15, 2022
2022 (Q2)
-0.08 / -0.27
0.214-227.57% (-0.49)――
Apr 20, 2022
2021 (Q4)
0.06 / 0.01
0.005120.00% (<+0.01)――
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

GB:OXB Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Mar 26, 2026
606.00 p575.00 p-5.12%
Sep 23, 2025
630.00 p589.00 p-6.51%
Apr 09, 2025
256.00 p232.50 p-9.18%
Sep 23, 2024
357.00 p360.00 p+0.84%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Oxford BioMedica plc (GB:OXB) report earnings?
Oxford BioMedica plc (GB:OXB) is schdueled to report earning on Sep 23, 2026, TBA (Confirmed).
    What is Oxford BioMedica plc (GB:OXB) earnings time?
    Oxford BioMedica plc (GB:OXB) earnings time is at Sep 23, 2026, TBA (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is the P/E ratio of Oxford BioMedica plc stock?
          The P/E ratio of Oxford BioMedica is N/A.
            What is GB:OXB EPS forecast?
            GB:OXB EPS forecast for the fiscal quarter 2026 (Q2) is -0.24.